Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclophosphamide + doxorubicin + lithium carbonate + paclitaxel
- Development stage
- Preclinical
- Lead developer
- Takeda
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A combination chemotherapy regimen consisting of cyclophosphamide, doxorubicin, and paclitaxel with lithium carbonate as a supportive agent. The AC-T portion (doxorubicin, cyclophosphamide, followed by paclitaxel) is a standard chemotherapy regimen for breast cancer, while lithium carbonate is being studied as an addition to reduce chemotherapy-induced neutropenia. Each component has a distinct mechanism of action: doxorubicin damages DNA inside cancer cells, cyclophosphamide attaches to and damages DNA in cancer cells during their resting phase, paclitaxel damages the cellular structure supporting cancer cells, and lithium carbonate helps increase neutrophil counts.
- Other names
- AC-T with lithium carbonate
02
Targets
GSK3 (Glycogen synthase kinase 3 beta)TOP2A (DNA topoisomerase II)DNAIMPA1 (Inositol Monophosphatase)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on cyclophosphamide + doxorubicin + lithium carbonate + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclophosphamide + doxorubicin + lithium carbonate + paclitaxel.